Points

New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Scientists at Affymetrix, Inc. (Nasdaq: AFFX) reported today in Science magazine online that they have completed a high-resolution scan of structure and function for nearly 30 percent of the human genome sequence. In collaboration with the National Cancer Institute, the research team used high-density GeneChip(R) microarrays to study every fifth base, on average, of 10 human chromosomes; they fou...

New study pinpoints epicenters of Earth's imminent extinctions

Safeguarding 595 sites around the world would help stave off an imminent global extinction crisis, according to new research published today in the Proceedings of the National Academy of Sciences ( Conducted by scientists working with the 52 member organizations of the Alliance for Zero Extinction (AZE –?<A HREF="http://www.zeroextinction.org...

Radiotherapy advance points way to noninvasive brain cancer treatment

With an equal rate of incidence and mortality-the number of those who get it, and the number of those who die from it-Glioblastoma Multiforme (GBM) is a brain cancer death sentence. Of the approximately 12,000 people who are diagnosed with GBM annually in the U.S., half will die within a year, and the rest within 3 years. Currently, the only treatments that stretch survival limits are exce...

Study pinpoints protein's role in cancer spread

Edinburgh scientists have identified the way a specific cell protein can trigger the spread of cancer. The study by researchers in the Cell Signalling Unit, University of Edinburgh Cancer Research Centre could pave the way for new drugs which limit the protein's ability to turn a normal cell cancerous. The protein, MDM2, normally functions to control the activity of a key cancer preventi...

Prion find points way to test for human 'mad cow' disease

In the July 7, 2006, issue of the journal Science, researchers at the University of Texas Medical Branch at Galveston (UTMB) describe experiments that may soon lead to a test that will enable medical science to estimate how many people are infected with the human form of mad cow disease, which can take as long as 40 years before manifesting itself. Such a blood test could also help preven...

More>>

Points at Biology Products

No data found

Search Points biology products at Google

Search Points biology products at Yahoo

Search Points biology products at Msn

Points at Biology Technology

Covance Appoints Co-Presidents for Early Development Services

PRINCETON, NJ - Covance Inc. has promoted Wendel Barr to the position of president, early development, in Madison, Wis., and Anthony Cork to the position of president, early development, in Harrogate, UK. The company said the move supports the regional decision-making employed by its clients in the preclinical segment. With the promotion, Wendel and Tony have become corporate senior vic...

Sharon Ethanol appoints operations director

, a subsidiary of <a href="http://www.grainnet.com/articles/Global_Renewable_LLC_Unveils_Plans_for...

More access points for Madison wireless

Now, , which provides wireless Internet service in a 10-block radius of Madison's Capitol Square a...

Kyron appoints former AMA chairman to board

Dr. Timothy Flaherty, former chairman of the , a comp...

Brady appoints GE efficiency expert as CTO

Tatterson, who brings expertise in process and product innovation, materials development, and chemical engineeri...

More>>

Points at Medicine News

Study points out that HIV vaccine may not be accepted easily

Researchers feel that in the next ten years, the HIV vaccine will be ready for use, but there may// be a lot of barriers preventing the acceptance of the vaccine by the people. The research done by University of Toronto researchers said that it is important that the health workers of the world gets the common people ready for accepting the vaccine, which may be quite difficult job to d...

Radiology advance points way to non-invasive brain cancer treatment

Glioblastoma Multiforme, GBM, is a brain cancer death sentence. It is the most lethal cancer there is. Of the approximately 12,000 people who are diagnosed with GBM annually in the U.S., half // will die within a year, and the rest within 3 years. The treatments include highly invasive surgeries to remove the tumor and radiation treatment with the maximum tolerated dose, both leading t...

New Research Points To Prevention Of Mad Cow Disease

It might not be long before researchers find appropriate genetic manipulation techniques to prevent bovine spongiform encephalopathy (BSE) or Mad Cow Disease//, as it is commonly known. Scientists at Texas A&M University have been able to successfully knock down disease causing genes in a goat fetus, produced through cloning. The same technique can be exploited to induce disease resis...

Four Points to Live up to 100

The secret of a long life seems to boil down to four factors: diet, exercise, psycho-spiritual and social.// Indeed, what does it take to live to the ripe age of 100? Scientistshave listed 10 commandments for a long life - and alcohol is one ofthem. They say that if you follow the simple rules, you have a fairchance of joining the growing number of centenarians across the globe....

Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development

West Nile virus evades the body’s immune defenses by blocking immune signaling by a protein receptor, a finding that could pave the way for a vaccine// to protect against North American strains of the virus, UT Southwestern Medical Center researchers report. Researchers discovered the receptor’s key role in controlling West Nile infection by conducting a study, described in October’s J...

More>>

Points at Medicine Products

Weck-Cel Points

Description:Weck-Cel Triangle shaped spearhead, set on a malleable, polypropylene handle, is designed for use in delicate, surgical areas. Maintains rigidity during wicking process. Single use, packaged sterile....
Company:Medtronic Xomed, Inc.

Weck-Cel Points and Strips

Description:Weck-Cel Triangle shaped spearhead, set on a malleable, polypropylene handle, is designed for use in delicate, surgical areas. Maintains rigidity during wicking process. Single use, packaged sterile....
Company:Medtronic Xomed, Inc.

Reduction Forceps with Points

Description:Reduction Forceps with Points for precise reduction of bone fragments with minimal soft tissue contact....
Company:Synthes, Inc.

Points at Medicine Technology

Medivation's Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy

- Aggregate Benefit over Placebo Larger at One Year than at SixMonths - SAN FRANCISCO and WASHINGTON, June 11, 2007/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that thebenefits of Dimebon over placebo in its double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer'sdisease were statistically significant on all five study endpointsat 12 months. Importantl...

GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines

Investigational vaccine could offer protectionfor infants against type b andmeningococcal disease — GlaxoSmithKline (GSK) announced results from aPhase II vaccine clinical study presented this week at thePediatri...

Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints

DENVER--(BUSINESS WIRE)--Apr 24, 2007 - Ceragenix PharmaceuticalsInc. (OTCBB:CGXP) today announced positive results from itspost-clearance marketing study comparing EpiCeram's(TM) efficacy tothat of Cutivate(R) cream, a mid-strength topical steroid in thetreatment of moderate-to-severe atopic dermatitis (AD). The study, which took place at five centers, consisted of 113pediatric patients,...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausiblyconfounded by survival benefit of post-study treatment with ERBITUX- NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced detailed results from the EPIC study - a randomized,open-label, multi-center Phase III trial - comparing ERBITUX(R)(Cetuximab) plus...

DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp.(Nasdaq:DYAX) announced today positive topline results from itsPhase 3, placebo-controlled trial, EDEMA3, for its lead productcandidate DX-88 (ecallantide), for hereditary angioedema (HAE). Awebcast presentation of the EDEMA3 data is scheduled for Tuesday,April 17, 2007 at 12:30 p.m. ET. DX-88, an internally discovered, recombina...

More>>